目的 建立注射用鹽酸倍他司汀臨床合理用藥評價(jià)標(biāo)準(zhǔn)，為臨床合理應(yīng)用提供參考。方法 以注射用鹽酸倍他司汀藥品說明書為基礎(chǔ)，參考相關(guān)指南和專家共識為依據(jù)，采用AHP-TOPSIS方法對安徽醫(yī)科大學(xué)附屬六安醫(yī)院2023年1月—12月使用注射用鹽酸倍他司汀病歷的用藥合理性進(jìn)行評價(jià)。結(jié)果 共納入165份病歷，其中相對接近度（Ci）≥0.8病歷評級為合理，共15例（占比9.09%）；0.6≤Ci＜0.8病歷評級為基本合理，共86例（占比52.12%）；Ci＜0.6病歷評級為不合理，共64例（占比38.79%）。注射用鹽酸倍他司汀用藥不合理用藥主要表現(xiàn)在適應(yīng)證、溶媒、給藥方式、特殊人群以及療效評價(jià)等方面。結(jié)論 本院注射用鹽酸倍他司汀的使用仍存在許多問題，需要加強(qiáng)管理?；贏HP-TOPSIS的評價(jià)方法科學(xué)合理，為藥物合理性評價(jià)提供了新的方法。

Objective To establish the evaluation criteria for clinical rational drug use of Betahistine Hydrochloride for Injection, and to provide reference for clinical rational application. Methods Based on the drug instructions of Betahistine Hydrochloride for Injection, referring to relevant guidelines and expert consensus, AHP-TOPSIS method was used to evaluate the rationality of the use of Betahistine Hydrochloride for Injection in the Lu’an Hospital Affiliated to Anhui Medical University from January to December 2023. Results A total of 165 medical records were included, of which 15 cases (9.09 %) had a reasonable Ci ≥ 0.8 medical record rating, 86 cases ( 52.12 % ) had a basically reasonable 0.6 ≤ Ci < 0.8 medical record rating, and 64 cases (38.79 %) had an unreasonable Ci < 0.6 medical record rating. The irrational use of Betahistine Hydrochloride for Injection is mainly manifested in indications, solvents, administration methods, special populations and efficacy evaluation. Conclusion There are still many problems in the use of Betahistine Hydrochloride for Injection in the hospital, and management needs to be strengthened. The evaluation method based on AHP-TOPSIS is scientific and reasonable, which provides a new method for the evaluation of drug rationality.

R971

安徽高校自然科學(xué)研究項(xiàng)目(KJ2021A0342);六安市科技局科研項(xiàng)目(2022lakj036)